Background: Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients.
Objective: Obtain real-world evidence for the use of biologics that target different segments of the immune system in patients with moderate-to-severe psoriasis.
Methods: A retrospective chart review was conducted for 100 patients who initiated biologic therapy and had a follow-up visit within a 4- to 12-month period. Efficacy assessments included body surface area (BSA), Physician’s Global Assessment (PGA) scores, composite BSA×PGA scores, and the National Psoriasis Foundation (NPF) Treat to Target (TTT) goal of ≤1% BSA.
Results: Biologic treatment led to notable reductions in BSA, PGA, and BSA×PGA relative to baseline, with the majority (67.0%) of the population achieving NPF TTT goals at follow-up. Disease improvements were observed in all patients, regardless of baseline body weight, prior experience with biologics, or the specific immune target of the prescribed biologic.
Conclusion: Long-term biologic therapy demonstrated effectiveness in treating patients with moderate-to-severe psoriasis. J Drugs Dermatol. 20(4):442-449. doi:10.36849/JDD.2021.5823Visit the Psoriasis Resource Center for more.